In a 65-year-old woman with amyotrophic lateral sclerosis who presents with progressive dyspnea, daytime fatigue, and morning headaches, with normal cardiac examination, normal B-type natriuretic peptide, and normal pulse oximetry, what is the most appropriate next step in management?

Perform Pulmonary Function Testing (PFT) Immediately

The most appropriate next step is to perform pulmonary function testing including spirometry (FVC), maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), and peak cough flow (PCF), as this patient with ALS presenting with progressive dyspnea, morning headaches, and daytime fatigue has classic symptoms of nocturnal hypoventilation and likely needs noninvasive ventilation (NIV) initiation 1.

Clinical Reasoning

This patient's symptom triad is pathognomonic for respiratory muscle weakness with nocturnal hypoventilation in ALS:

• Morning headaches = CO2 retention during sleep
• Daytime fatigue = poor sleep quality from hypoventilation
• Progressive dyspnea = inspiratory muscle weakness

The normal cardiac examination and BNP effectively rule out heart failure, while the normal resting pulse oximetry (95%) is misleading—daytime oximetry is insensitive for detecting nocturnal hypoventilation in neuromuscular disease 1, 2.

The PFT-Driven Algorithm

Based on the 2023 CHEST guidelines 1, proceed as follows:

Step 1: Obtain PFT measurements

• FVC (forced vital capacity)
• MIP (maximum inspiratory pressure)
• MEP (maximum expiratory pressure)
• PCF (peak cough flow)
• SNIP (sniff nasal inspiratory pressure) if MIP cannot be reliably obtained

Step 2: Apply NIV initiation criteria

Initiate NIV if ANY of the following are met 1:

• FVC < 80% predicted with symptoms (which this patient has) OR FVC < 50% without symptoms
• MIP < 60 cm H₂O
• MEP < 40 cm H₂O
• PCF < 270 L/min (age ≥12 years)
• SNIP < 70 cm H₂O (males) or < 60 cm H₂O (females)

Step 3: If PFT criteria are met

Start NIV immediately without waiting for polysomnography or overnight oximetry in adults 1. The clinical presentation is sufficient.

Step 4: If PFT criteria are NOT met (unlikely given symptoms)

Proceed to overnight oximetry or polysomnography to document:

• SpO₂ ≤ 90% for ≥ 2% of sleep time
• PaCO₂ > 45 mm Hg on arterial blood gas

Critical Pitfalls to Avoid

1. Do not rely on normal daytime pulse oximetry to exclude respiratory failure—nocturnal hypoventilation occurs first and daytime oximetry remains normal until late-stage disease 2

2. Do not wait for polysomnography if PFT criteria are met with symptoms—this delays life-prolonging therapy 1

3. Do not attribute symptoms to cardiac causes based solely on comorbidities when the clinical picture fits neuromuscular respiratory failure 3

4. Morning headaches are a red flag symptom requiring urgent evaluation—they indicate CO₂ retention during sleep 1, 2

Why This Matters for Outcomes

NIV is the only intervention proven to prolong survival and improve quality of life in ALS 4, 5, 6. Early initiation when respiratory symptoms first appear (as in this patient) maximizes benefit. Respiratory failure is the leading cause of death in ALS, and the window for effective NIV intervention narrows as bulbar dysfunction progresses 1.

The 2023 CHEST guidelines emphasize that PFT should be performed every 6 months in ALS patients at baseline, but symptomatic patients require immediate testing regardless of the interval since last assessment 1.